Abaloparatide Real-World Patient Experience Study

Deborah T. Gold, Richard Weiss, Tammy Beckett, Chad Deal, Robert S. Epstein, Andrew L. James, Jacqueline M. Kernaghan, Mahshid Mohseni, Michael Spiegel, Tamara Vokes, Jenna Roberts, Tom Bailey, Yamei Wang, Setareh A. Williams

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection. Eight geographically diverse secondary care sites in the United States participated (n = 193). Mean ± SD age was 67.4 ±8.62 years. Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important. The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%). All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence. Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose. Although injecting medication (18%) and higher out-of-pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives. In multivariable analyses, ease of preparation (OR = 2.62; 95% CI, 1.01–6.81; p = 0.048) and fracture history (OR = 1.72; 95% CI, 1.03–2.86; p = 0.037) were significantly associated with overall satisfaction. Ease of preparation was a predictor of higher satisfaction with treatment convenience (coefficient = 13.60; 95% CI, 8.08–19.12; p = 0.00). Remembering to take the medication was a significant predictor of self-reported adherence (OR = 16.66; 95% CI, 3.30–84.24; p = 0.001). In conclusion, the majority of patients were satisfied with ABL and found it convenient/easy to prepare and store. High self-reported adherence may be associated with positive patient experience including ease of use and adequate support from healthcare providers.

Original languageEnglish
Article numbere10457
JournalJBMR Plus
Volume5
Issue number3
DOIs
StatePublished - Mar 2021

Keywords

  • ANABOLICS
  • HEALTH SERVICES RESEARCH
  • OSTEOPOROSIS

Fingerprint

Dive into the research topics of 'Abaloparatide Real-World Patient Experience Study'. Together they form a unique fingerprint.

Cite this